NCT02868632 - Study of Immune Checkpoint Inhibition With Radiation Therapy in Unresectable, Non-metastatic Pancreatic Cancer | Biotech Hunter

Timeline

Start Date

August 7, 2016

Primary Completion Date

March 4, 2019

Study Completion Date

March 4, 2019

Conditions

Pancreatic Cancer

Interventions

DRUG

MEDI4736

anti-PD-L1 human monoclonal antibody

DRUG

Tremelimumab

anti-CTLA4 human monoclonal antibody

RADIATION

Stereotactic Body Radiation Therapy (SBRT)

Stereotactic body radiation therapy (SBRT) will be administered at the standard dose of 6 Gy daily for 5 days.

Trial Locations (3)

New York University School of Medicine, New York

Montefiore Medical Center, The Bronx

Georgetown University Medical Center, Washington D.C.